Trials / Completed
CompletedNCT06531746
Effect of Extracorporeal Shock Wave on Electrophysiological Changes and Pain in Patients With Lower Cross Syndrome
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Ahmed Alshimy · Academic / Other
- Sex
- All
- Age
- 30 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Lower Cross Syndrome happens when there is muscular imbalance between weak and tight muscles. The tight muscles are generally the hip flexors and erector spinae, and weak muscles are the abdominals and gluteal muscles. Shortening occurs in the hip flexors while weakening occurs in the abdominals and gluteal muscles.
Detailed description
Group I (Study): will consist of 20 patients with lower cross syndrome and will receive extracorporeal shock wave in addition to conventional physical therapy program. For 12 sessions every other day, each session for 1 hour. Group II (Control): will consist of 20 patients with lower cross syndrome and will receive sham extracorporeal shock wave in addition to conventional physical therapy program only same as group (I). For 12 sessions every other day, each session for 1 hour.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Extracorporeal shock wave | participants will receive 2000 ESWT impulses, with 1500 targeting the taut band and 500 surrounding the taut band, with an energy flux density of 0.10 mJ/mm and frequency of 8 Hz, by using an EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number: EM12681015\], Italy, shock wave generator. |
| OTHER | Conventional physical therapy program | Stretching and strengthening of Iliopoas muscle and Stretching and strengthening of Lower back muscles |
| DEVICE | Sham (No Treatment) | Sham extracorporeal shock wave will be introduced without real shock wave impulses. |
Timeline
- Start date
- 2025-02-02
- Primary completion
- 2025-11-28
- Completion
- 2025-11-29
- First posted
- 2024-08-01
- Last updated
- 2025-12-05
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06531746. Inclusion in this directory is not an endorsement.